sur INNATE PHARMA (EPA:IPH)
Innate Pharma presents its innovations in oncology at SITC 2024
Immunotherapeutics company Innate Pharma has unveiled new data on its promising anti-tumor agents. At the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, the company will present its latest preclinical advances on two of its flagship projects: IPH6501 and IPH4502. These two drug candidates exemplify Innate’s commitment to pushing the frontiers of immuno-oncology.
IPH6501, a tetra-specific NK cell engager, shows promising potential against refractory B-cell lymphomas. Designed to engage multiple NK cell receptors, it specifically targets the tumor antigen CD20. In addition, IPH4502, a novel antibody-drug conjugate, targets Nectin-4, a protein overexpressed in several solid cancers. Each presentation makes a significant contribution in the fight against cancer.
These findings will also be shared at the Protein & Antibody Engineering Summit (PEGS) Europe. Innate’s involvement in these events reinforces its leadership position in oncology therapeutic innovation.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INNATE PHARMA